Immunocore's Phase 1/2 trial data reveal that combining brenetafusp with KIMMTRAK in first-line metastatic uveal melanoma patients achieved a 70% estimated two-year overall survival rate, with median overall survival not reached after 29 months. The combination showed a 29% overall response rate and a 71% disease control rate, with manageable safety profiles. This is the first evidence of clinical activity from two T cell engagers combined in a solid tumor, prompting plans for a Phase 2/3 randomized trial to further evaluate this promising treatment option.
Immunocore's Phase 1/2 trial data show a 70% estimated two-year overall survival rate for metastatic uveal melanoma patients treated with brenetafusp plus KIMMTRAK. For readers following the health sector, here is Pluang's market snapshot as of Nov 06, 2026 23:12 WIB: out of 150 priced US health stocks, 76 rose and 72 fell. Notable movers include CGC at USD 0.61 with a -9.72% change and 100% sell order activity, DNA at USD 10.82 with +8.63% and 100% buy order activity, and SMMT at USD 15.26 with +7.51% and balanced buy/sell activity.
Ipsen has disclosed its monthly update on the total number of shares and voting rights as of October 31, 2026. The company reported 83,814,526 shares composing the share capital, with a gross total of 132,059,377 voting rights and a net total of 130,...
Ipsen Pharma has disclosed the total number of shares and voting rights composing its capital as of October 31, 2026. The company reported 83,814,526 shares and a gross total of 132,059,377 voting rights, with a net total of 130,677,690 after excludi...
At its 2026 International User Summit, Chery unveiled its Globalization 3.0 strategy, moving beyond export-driven growth to emphasize deep localization, sustainable development, and community engagement. The company is expanding local R&D, manufactur...
Sodexo disclosed its monthly update on share capital and voting rights as of October 31, 2026. The company has 147,454,887 shares with actual voting rights totaling 216,485,145, reflecting shares with single and double voting rights. This update is p...
Sodexo announced its monthly update on the total number of shares and voting rights as of October 31, 2026. The company has 147,454,887 shares composing its capital, with 216,485,145 exercisable voting rights and 218,335,896 theoretical voting rights...
